西格列汀治疗2型糖尿病的效果观察

Observation of therapeutic effect of sitagliptin on type 2 diabetes mellitus

目的探讨西格列汀治疗2型糖尿病(T2DM)的临床效果。方法抽取2020年10月至2022年1月泰安荣军医院收治的T2DM患者73例,按照随机数字表法将其分为阿卡波糖组(36例)与西格列汀组(37例),比较两组血糖水平[空腹血糖(FPG)、餐后2 h血糖(2hPG)、糖化血红蛋白(HbA1c)]、胰岛功能指标[胰岛素抵抗指数(HOMA-IR)与胰岛素分泌指数(HOMA-β)]、炎症指标[血清淀粉样蛋白A(SAA)、C反应蛋白(CRP)、白细胞介素6(IL-6)]、氧自由基[3-硝基酪氨酸(3-NT)、超氧化物歧化酶(SOD)、丙二醛(MDA)]及不良反应发生情况。结果治疗后,西格列汀组FPG、2hPG、HbA1c均低于阿卡波糖组(t=2.46、2.09、2.37,P均<0.05);西格列汀组HOMA-IR低于阿卡波糖组(t=2.58,P<0.05),HOMA-β高于阿卡波糖组(t=2.56,P<0.05);西格列汀组SAA、CRP、IL-6水平均低于阿卡波糖组(t=6.23、4.11、4.42,P均<0.05);西格列汀组3-NT、MDA水平均低于阿卡波糖组(t=2.27、3.00,P均<0.05),SOD水平高于阿卡波糖组(t=2.29,P<0.05);西格列汀组不良反应总发生率(5.41%,2/37)低于阿卡波糖组(25.00%,9/36),P<0.05。结论西格列汀治疗T2DM可以有效控制患者血糖水平,提高胰岛功能,改善机体炎症反应,且安全性好。

Objective To investigate the efficacy of sitagliptin in the treatment of type 2 diabetes mellitus(T2DM).Methods A total of 73 patients with T2DM admitted to Taian Disabled Soldier’s Hospital from October 2020 to January 2022 were selected,and the patients divided into acarbose group(36 cases)and sitagliptin group(37 cases)according to random number table method.Blood glucose levels including fasting blood glucose(FPG),2-hour postprandial blood glucose(2hPG)and glycosylated hemoglobin(HbA1c),islet function indicators assessed by insulin resistance index(HOMA-IR)and insulin secretion index(HOMA-β),inflammation indicators including serum amyloid A(SAA),C-reactive protein(CRP)and interleukin-6(IL-6),oxygen free radicals such as 3-nitrotyrosine(3-NT),superoxide dismutase(SOD)and malondialdehyde(MDA),and occurrence of adverse reactions were compared between the two groups.Results After treatment,FPG,2hPG and HbA1c in the sitagliptin group were lower than those in the acarbose group(t=2.46,2.09,2.37;all P<0.05).The HOMA-IR of the sitagliptin group was lower than that of the acarbose group(t=2.58,P<0.05),and the HOMA-βof the sitagliptin group was higher than that of the acarbose group(t=2.56,P<0.05).The levels of SAA,CRP and IL-6 in the sitagliptin group were lower than those in the acarbose group(t=6.23,4.11,4.42;all P<0.05).The levels of 3-NT and MDA in the sitagliptin group were lower than those in the acarbose group(t=2.27,3.00;all P<0.05),the SOD level of the sitagliptin group was higher than that of the acarbose group(t=2.29,P<0.05).The total incidence of adverse reactions in the sitagliptin group(5.41%,2/37)was lower than that of the acarbose group(25.00%,9/36),P<0.05.Conclusions Sitagliptin in the treatment of T2DM can effectively control blood glucose levels,improve islet function,and improve body inflammation,with good safety.